Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) insider Ariel Hurley sold 3,203 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total value of $296,661.86. Following the transaction, the insider now directly owns 18,270 shares in the company, valued at approximately $1,692,167.40. The trade was a 14.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Ariel Hurley also recently made the following trade(s):
- On Monday, January 13th, Ariel Hurley sold 2,250 shares of Blueprint Medicines stock. The stock was sold at an average price of $100.00, for a total value of $225,000.00.
- On Thursday, December 12th, Ariel Hurley sold 1,819 shares of Blueprint Medicines stock. The shares were sold at an average price of $93.26, for a total transaction of $169,639.94.
Blueprint Medicines Stock Down 0.4 %
Shares of BPMC stock opened at $89.38 on Wednesday. The company has a market capitalization of $5.71 billion, a price-to-earnings ratio of -82.76 and a beta of 0.62. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The company's fifty day moving average price is $99.50 and its 200-day moving average price is $94.34. Blueprint Medicines Co. has a one year low of $80.68 and a one year high of $121.90.
Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Sell-side analysts expect that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.
Analyst Ratings Changes
BPMC has been the subject of several research reports. StockNews.com cut shares of Blueprint Medicines from a "hold" rating to a "sell" rating in a report on Monday. HC Wainwright reiterated a "buy" rating and set a $135.00 target price on shares of Blueprint Medicines in a research note on Friday, February 14th. Wedbush reissued an "outperform" rating and set a $128.00 price target on shares of Blueprint Medicines in a report on Friday, February 28th. Piper Sandler lifted their price objective on Blueprint Medicines from $109.00 to $119.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $133.00 target price on shares of Blueprint Medicines in a report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Blueprint Medicines presently has an average rating of "Moderate Buy" and a consensus price target of $123.83.
Read Our Latest Report on BPMC
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Blueprint Medicines by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 6,774,884 shares of the biotechnology company's stock valued at $590,905,000 after buying an additional 91,450 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Blueprint Medicines by 5.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,679,089 shares of the biotechnology company's stock valued at $495,331,000 after acquiring an additional 291,822 shares during the last quarter. Wellington Management Group LLP lifted its stake in Blueprint Medicines by 8.0% in the 4th quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock worth $373,421,000 after purchasing an additional 316,754 shares in the last quarter. State Street Corp lifted its stake in Blueprint Medicines by 16.2% in the 3rd quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company's stock worth $255,827,000 after purchasing an additional 385,818 shares in the last quarter. Finally, William Blair Investment Management LLC boosted its holdings in shares of Blueprint Medicines by 16.1% during the 4th quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company's stock valued at $169,616,000 after purchasing an additional 269,896 shares during the last quarter.
Blueprint Medicines Company Profile
(
Get Free Report)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
